PROMISING EARLY OUTCOMES WITH A NOVEL, COMPLETE STEROID AVOIDANCE IMMUNOSUPPRESSION PROTOCOL IN PEDIATRIC RENAL TRANSPLANTATION1
暂无分享,去创建一个
Steve Alexander | Minnie M. Sarwal | Amir Belson | M. Sarwal | O. Salvatierra | P. Yorgin | Oscar Salvatierra | A. Belson | Peter D. Yorgin | Maria T. Millan | Natasha Belanger | Laura Granucci | Cyd Major | Cathy Costaglio | Jaime Sanchez | Pamela Orlandi | M. Millan | S. Alexander | Jaime Sánchez | Cyd Major | Laura Granucci | P. Orlandi | Natasha Belanger | Cathy Costaglio
[1] K. Lemley,et al. Superior outcomes in pediatric renal transplantation. , 1997, Archives of surgery.
[2] T. Strom,et al. Trends in the use of glucocorticoids in renal transplantation. , 1994, Transplantation.
[3] S. Birkeland. Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy. , 1998, Transplantation.
[4] D. Watkin,et al. REHABILITATION IN SCHIZOPHRENIA. , 1965, Lancet.
[5] E. Avner,et al. Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. A report of the North American Pediatric Renal Transplant Cooperative Study. , 1996, Transplantation.
[6] R. Merion,et al. Corticosteroid withdrawal after liver transplantation. , 1995, Surgery.
[7] C. Ware,et al. Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: inhibition of Fas ligand expression by retinoic acid and glucocorticoids , 1995, The Journal of experimental medicine.
[8] M. Stegall,et al. Prednisone withdrawal late after adult liver transplantation reduces diabetes, hypertension, and hypercholesterolemia without causing graft loss , 1997, Hepatology.
[9] B. Kiberd,et al. CONVERSION TO RAPAMYCIN IMMUNOSUPPRESSION IN RENAL TRANSPLANT RECIPIENTS: REPORT OF AN INITIAL EXPERIENCE1 , 2000, Transplantation.
[10] G. Tisone,et al. Retrospective analysis of 30 patients who underwent liver transplantation without use of steroids. , 1999, Transplantation proceedings.
[11] G. Tydén,et al. Hypertriglyceridemia in renal transplant recipients treated with sirolimus. , 1998, Transplantation proceedings.
[12] T. Bunchman. Compliance in pediatric transplant , 2000, Pediatric transplantation.
[13] Z. Massy. HYPERLIPIDEMIA AND CARDIOVASCULAR DISEASE AFTER ORGAN TRANSPLANTATION , 2001, Transplantation.
[14] P. Ratcliffe,et al. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression , 1996, The Lancet.
[15] F. Vincenti,et al. Histopathologic findings from 2-year protocol biopsies from a U.S. multicenter kidney transplant trial comparing tacrolimus versus cyclosporine , 1998 .
[16] D. Stablein,et al. The 1997 Annual Renal Transplantation in Children Report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS) , 1999, Pediatric transplantation.
[17] L. Burrows,et al. Risk of steroid withdrawal in pediatric renal allograft recipients (a 5-year follow-up). , 1994, Clinical transplantation.
[18] P. Nickerson,et al. Beneficial effects of treatment of early subclinical rejection: a randomized study. , 1998, Journal of the American Society of Nephrology : JASN.
[19] J. Chapman,et al. EFFECT OF HISTOLOGICAL DAMAGE ON LONG-TERM KIDNEY TRANSPLANT OUTCOME , 2001, Transplantation.
[20] J. Barry,et al. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. , 2000, Transplantation.
[21] B. Kahan. Sirolimus: a new agent for clinical renal transplantation. , 1997, Transplantation proceedings.
[22] H. E. Hansen,et al. The Banff 97 working classification of renal allograft pathology. , 1999, Kidney international.